Systematic review and meta-analysis of robotic radical hysterectomy vs. open radical hysterectomy for early stage cervical cancer

Greg Marchand , Ahmed Taher Masoud , Ahmed Abdelsattar , Amanda Arroyo , Carmen Moir , Daniela Gonzalez Herrera , Madison Blanco , Kate Ruffley , Brooke Hamilton , Mary Petersen , Sarena Fernandez , Hollie Ulibarri
{"title":"Systematic review and meta-analysis of robotic radical hysterectomy vs. open radical hysterectomy for early stage cervical cancer","authors":"Greg Marchand ,&nbsp;Ahmed Taher Masoud ,&nbsp;Ahmed Abdelsattar ,&nbsp;Amanda Arroyo ,&nbsp;Carmen Moir ,&nbsp;Daniela Gonzalez Herrera ,&nbsp;Madison Blanco ,&nbsp;Kate Ruffley ,&nbsp;Brooke Hamilton ,&nbsp;Mary Petersen ,&nbsp;Sarena Fernandez ,&nbsp;Hollie Ulibarri","doi":"10.1016/j.hsr.2023.100109","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Recent data has brought into question the safety of minimally invasive techniques for radical hysterectomy in the treatment of early stage cervical cancer. After the publication of several new studies, we aimed to compare robotic radical hysterectomy (RRH) with open radical hysterectomy (ORH) in the management of women with early stage cervical cancer, while excluding minimally invasive cases performed without robotic assistance.</p></div><div><h3>Data Sources</h3><p>We searched six databases from inception until 11/30/2021. The original search found 233 unique papers, and ultimately 35 studies, comprising 11,888 total radical hysterectomies, met criteria for our final analysis. We included all studies including the intervention of RRH for early stage cervical cancer, with the comparator of ORH. We included randomized clinical trials (RCTs), case-control, retrospective cohort, and prospective cohort. We included studies that had robotic and laparoscopic arms, but excluded any studies that did not specifically provide specific data as to each group. We analyzed continuous data using mean difference and a 95% confidence interval, while dichotomous data were analyzed using odds ratio and a 95% confidence interval.</p></div><div><h3>Results</h3><p>We found that there was no significant difference between RRH and ORH regarding five-year Overall Survival (OR=1.28[0.66,2.46], (<em>P</em> = 0.46)), disease free survival (OR=0.94[0.77,1.14], (<em>P</em> = 0.51)), or recurrence (OR=0.92[0.75,1.13], (<em>P</em> = 0.44)) intraoperative complications (OR=0.75[0.55,1.02], (<em>P</em> = 0.07)), or mortality (OR=0.81[0.53,1.22], (<em>P</em> = 0.31)).</p><p>We found that RRH was better than ORH in terms of estimated blood loss (MD=-397.95[-471.65,-324.24], (<em>P</em> &lt; 0.001)), blood transfusion rate (OR=0.13[0.10,0.17], (<em>P</em> = 0.001), post-operative complications (OR=0.65[0.46,0.91], (<em>P</em> = 0.01)), and length of hospital stay (MD=-3.99[-4.67,-3.31], (<em>P</em> &lt; 0.001)). While ORH was better than RRH regarding operation time (MD=15.34[2.21,28.47], (<em>P</em> = 0.02)) and number of resected lymph nodes (MD=-2.64[-4.12,-1.15], (<em>P</em> = 0.005)).</p></div><div><h3>Conclusions</h3><p>The previously seen increase in cancer recurrence and decrease in survival no longer seem to be present when we consider the newest high-quality data and exclude non-robotic minimally invasive techniques. RRH was associated with less estimated blood loss, a lower transfusion rate, a shorter hospital stay, and fewer postoperative complications. ORH seems to be associated with a higher number of resected lymph nodes, and a shorter operative time.</p><p><strong>Trial registration details: Prospero Prospective Registration Number</strong>: CRD42022306991 <strong>Registration link</strong>: <span>https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=306991</span><svg><path></path></svg></p></div>","PeriodicalId":73214,"journal":{"name":"Health sciences review (Oxford, England)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health sciences review (Oxford, England)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772632023000351","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Recent data has brought into question the safety of minimally invasive techniques for radical hysterectomy in the treatment of early stage cervical cancer. After the publication of several new studies, we aimed to compare robotic radical hysterectomy (RRH) with open radical hysterectomy (ORH) in the management of women with early stage cervical cancer, while excluding minimally invasive cases performed without robotic assistance.

Data Sources

We searched six databases from inception until 11/30/2021. The original search found 233 unique papers, and ultimately 35 studies, comprising 11,888 total radical hysterectomies, met criteria for our final analysis. We included all studies including the intervention of RRH for early stage cervical cancer, with the comparator of ORH. We included randomized clinical trials (RCTs), case-control, retrospective cohort, and prospective cohort. We included studies that had robotic and laparoscopic arms, but excluded any studies that did not specifically provide specific data as to each group. We analyzed continuous data using mean difference and a 95% confidence interval, while dichotomous data were analyzed using odds ratio and a 95% confidence interval.

Results

We found that there was no significant difference between RRH and ORH regarding five-year Overall Survival (OR=1.28[0.66,2.46], (P = 0.46)), disease free survival (OR=0.94[0.77,1.14], (P = 0.51)), or recurrence (OR=0.92[0.75,1.13], (P = 0.44)) intraoperative complications (OR=0.75[0.55,1.02], (P = 0.07)), or mortality (OR=0.81[0.53,1.22], (P = 0.31)).

We found that RRH was better than ORH in terms of estimated blood loss (MD=-397.95[-471.65,-324.24], (P < 0.001)), blood transfusion rate (OR=0.13[0.10,0.17], (P = 0.001), post-operative complications (OR=0.65[0.46,0.91], (P = 0.01)), and length of hospital stay (MD=-3.99[-4.67,-3.31], (P < 0.001)). While ORH was better than RRH regarding operation time (MD=15.34[2.21,28.47], (P = 0.02)) and number of resected lymph nodes (MD=-2.64[-4.12,-1.15], (P = 0.005)).

Conclusions

The previously seen increase in cancer recurrence and decrease in survival no longer seem to be present when we consider the newest high-quality data and exclude non-robotic minimally invasive techniques. RRH was associated with less estimated blood loss, a lower transfusion rate, a shorter hospital stay, and fewer postoperative complications. ORH seems to be associated with a higher number of resected lymph nodes, and a shorter operative time.

Trial registration details: Prospero Prospective Registration Number: CRD42022306991 Registration link: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=306991

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
机器人子宫根治术与开放式子宫根治术治疗早期宫颈癌的系统评价与meta分析
目的最近的数据对微创根治性子宫切除术治疗早期宫颈癌的安全性提出了质疑。在几项新研究发表后,我们旨在比较机器人根治性子宫切除术(RRH)和开放式根治性子宫切除术(ORH)在治疗早期宫颈癌中的作用,同时排除无机器人辅助的微创病例。数据来源我们检索了六个数据库,从成立到11/30/2021。最初的搜索发现了233篇独特的论文,最终有35项研究,包括11,888例根治性子宫切除术,符合我们最终分析的标准。我们纳入了包括RRH干预早期宫颈癌的所有研究,并以ORH为比较物。我们包括随机临床试验(RCTs)、病例对照、回顾性队列和前瞻性队列。我们纳入了有机械臂和腹腔镜臂的研究,但排除了没有明确提供每组具体数据的研究。我们使用均值差和95%置信区间分析连续数据,使用优势比和95%置信区间分析二分类数据。结果RRH与ORH在5年总生存率(OR=1.28[0.66,2.46], (P = 0.46))、无病生存率(OR=0.94[0.77,1.14], (P = 0.51))、复发率(OR=0.92[0.75,1.13], (P = 0.44))、术中并发症(OR=0.75[0.55,1.02], (P = 0.07))、死亡率(OR=0.81[0.53,1.22], (P = 0.31))方面均无显著差异。我们发现RRH在估计失血量方面优于ORH (MD=-397.95[-471.65,-324.24], P <0.001)、输血率(OR=0.13[0.10,0.17], (P = 0.001)、术后并发症(OR=0.65[0.46,0.91], (P = 0.01))、住院时间(MD=-3.99[-4.67,-3.31], (P <0.001))。而ORH在手术时间(MD=15.34[2.21,28.47], (P = 0.02))和淋巴结切除数(MD=-2.64[-4.12,-1.15], (P = 0.005))上均优于RRH。结论当我们考虑到最新的高质量数据并排除非机器人微创技术时,先前看到的癌症复发率增加和生存率降低似乎不再存在。RRH与更少的估计失血量、更低的输血率、更短的住院时间和更少的术后并发症相关。ORH似乎与较高数量的淋巴结切除和较短的手术时间有关。试验注册详情:普洛斯彼罗前瞻性注册编号:CRD42022306991注册链接:https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=306991
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Health sciences review (Oxford, England)
Health sciences review (Oxford, England) Medicine and Dentistry (General)
自引率
0.00%
发文量
0
审稿时长
75 days
期刊最新文献
Deciphering the intricacies of immune system dysfunction and its impact on diabetes mellitus: Revisiting the communication strategies to manage diabetes mellitus Revolutionizing menopause management: Nonhormonal therapy for vasomotor symptoms Harnessing the power of natural products against bacterial urinary tract infections: A perspective review for cultivating solutions Unveiling the therapeutic potential of butein: A comprehensive review Advancements in ulcerative colitis management: A critical assessment of etrasimod therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1